Somnus raises series A to advance sleeping pill in Phase II
This article was originally published in Scrip
Executive Summary
Somnus Therapeutics, a private US firm developing a delayed-release sleep-maintenance therapy, has raised $15 million in a series A round. The financing was led by CTI Life Sciences Fund with Care Capital, the company's seed investor, also participating.